WM382

• CAT Number: I042606
• CAS Number: 2606990-92-3
• Molecular Formula: C29H36N4O4
• Molecular Weight: 504.62
• Purity: ≥95%
• Synonyms: (4R)-4-(2-amino-4,4-diethyl-6-oxo-5H-pyrimidin-1-yl)-N-[(4S)-2,2-dimethyl-3,4-dihydrochromen-4-yl]-3,4-dihydro-2H-chromene-6-carboxamide
• InChI: InChI=1S/C29H36N4O4/c1-5-29(6-2)17-25(34)33(27(30)32-29)22-13-14-36-23-12-11-18(15-20(22)23)26(35)31-21-16-28(3,4)37-24-10-8-7-9-19(21)24/h7-12,15,21-22H,5-6,13-14,16-17H2,1-4H3,(H2,30,32)(H,31,35)/t21-,22+/m0/s1
• InChIKey: ZSZSSSHEMYULPX-FCHUYYIVSA-N
• SMILES: CCC1(CC(=O)N(C(=N1)N)C2CCOC3=C2C=C(C=C3)C(=O)NC4CC(OC5=CC=CC=C45)(C)C)CC

WM382 (Cat No.: I042606) is a novel antimalarial compound under development as a potential treatment for Plasmodium falciparum malaria. It is a dual-targeting drug candidate designed to inhibit two essential enzymes: cytochrome bc1 and dihydroorotate dehydrogenase (DHODH), both critical for parasite survival. By simultaneously blocking mitochondrial respiration and pyrimidine biosynthesis, WM382 exhibits potent activity against both blood and liver stages of the parasite. Preclinical studies demonstrate its efficacy and favorable pharmacokinetics, making WM382 a promising candidate for next-generation antimalarial therapy with resistance-preventive potential.

Reference

[1]. Manuel de LR, et al. The Invention of WM382, a Highly Potent PMIX/X Dual Inhibitor toward the Treatment of Malaria. ACS Med Chem Lett. 2022 Oct 12.

[2]. Hodder AN, et al. Basis for drug selectivity of plasmepsin IX and X inhibition in Plasmodium falciparum and vivax. Structure. 2022 Jul 7;30(7):947-961.e6.
[Content Brief]

[3]. Favuzza P, et al. Dual Plasmepsin-Targeting Antimalarial Agents Disrupt Multiple Stages of the Malaria Parasite Life Cycle. Cell Host Microbe. 2020 Apr 8;27(4):642-658.e12.
[Content Brief]